On Friday 19 April, the European Commission announced that it was seeking the views of all interested parties on the commitments proposed by the pharmaceutical company Vifor to address the Commission’s concerns about possible anti-competitive behaviour (see EUROPE B12975A18).
Vifor held a dominant position in several national markets for the supply of intravenous iron-based medicines.
Following the opening of a formal investigation procedure in June 2022, the Commission is concerned that...